Serial Assessment of Cardiac Function during and following Mitoxantrone Infusion in 30 Consecutive Patients with Multiple Sclerosis

Immunosuppressive therapy is an established therapeutic option in patients suffering from multiple sclerosis (MS). In an open nonrandomized study we serially assessed cardiac function in 30 consecutive patients with MS before, during, and after mitoxantrone therapy. Mitoxantrone (12 mg/m2) was admin...

Full description

Saved in:
Bibliographic Details
Published inMultiple Sclerosis International Vol. 2010; no. 2010; pp. 2 - 5
Main Authors Franzen, Damian, Haus, Angelika, Hellmich, Martin
Format Journal Article
LanguageEnglish
Published Cairo, Egypt Hindawi Limiteds 01.01.2010
Hindawi Puplishing Corporation
Hindawi Publishing Corporation
Wiley
Subjects
Clinical Study
Online AccessGet full text

Cover

More Information
Summary:Immunosuppressive therapy is an established therapeutic option in patients suffering from multiple sclerosis (MS). In an open nonrandomized study we serially assessed cardiac function in 30 consecutive patients with MS before, during, and after mitoxantrone therapy. Mitoxantrone (12 mg/m2) was administered intravenously at 3-month intervals. Before each infusion, cardiac function was assessed by history taking, resting electrocardiogram, and echocardiography. Whereas no patient experienced clinical signs of heart failure, left ventricular pump function decreased continuously during mitoxantrone therapy and did not recover after cessation. The presented data suggest a dose-dependent and long-lasting toxic cardiac effect of low-dose mitoxantrone therapy in MS.
Bibliography:Academic Editor: Bruno Brochet
ISSN:2090-2654
2090-2662
DOI:10.1155/2010/351045